Home About Us Writing a Scientific Article Author's Instruction Contact us



/  /    MRJMMS Home   /   /    About MRJMMS    /  /    Submit Manuscripts    /  /      Call For Articles      / /     Editorial Board     / /    Archive     / /    Author's Guide  /  /


October 2017 Vol. 5 No.10

Other viewing option

• Full text
Reprint (PDF) (438 KB)

Search Pubmed for articles by:

Marinova R
Petrova G

Other links:
PubMed Citation
Related articles in PubMed



Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 5(10) pp. 495-499, October, 2017 

Copyright © 2017 Merit Research Journals

Original Research Article

Our ICU experience with non-invasive ventilation for acute exacerbations in adults with cystic fibrosis


Ralitsa Marinova1, Snezhina Lazova2, Filip Abadinov3 and Guergana Petrova2*


1Clinic of Anesthesiology and Intensive care, University Hospital “Alexandrovska”, Medical University- Sofia
2Clinic of Pediatrics, University Hospital "Alexandrovska", Department of Paediatrics, Sofia, Medical University – Sofia
3Clinic of Anesthesiology and Intensive care, University Hospital “Saint Ekaterina”, Medical University- Sofia

*Corresponding Author’s E-mail: gal_ps@yahoo.co.uk

Accepted October 09, 2017




We report our experience of using noninvasive ventilation (NIV) in 15 adult cystic fibrosis (CF) patients with chronic respiratory failure, admitted in intensive care unit (ICU) during episodes of acute infectious exacerbation. The mean age of the patients was 28.73 ± 5.66 years, 8 males and 7 females.Prior to ICU admission, all patients had had FEV1<51%. Oxygen saturation on room air was 83,5%±4.5 with PCO2 raging from 4.2 to 6.59 kPa. At admission all were initially treated with NIV to avoid adverse effects of tracheal intubation, none of the patient required intubation. We used NIV-BiPAP mode with 40% of oxygen, aiming to maintain stable hemodynamic in all patients. Settings were adjusted to arterial blood gas values. Once the SatO2 was stable 90% or over and PCO2 ranged from 4 to 5.29kPa the NIV was stopped in all but one patient. Length of stay in ICU was 13,13±5,35 days. All patients were discharged alive from the ICU. In the follow up a year after discharge we recorded 1 death, 4 patients included in lung-transplant waiting list, 3 patients in a process for lung transplant evaluation and the rest of the patients hadn’t required re-admissions in ICU. Our results confirm the published data that NIV can serve as a bridge towards lung transplantation for CF patients with end-stage lung disease and not merely prolonging the suffering. NIV improved hypoxia and fairly corrected hypercapnia in our patients. For these patients, there is a possibility of prolonging life if they are successfully treated for their acute episode of respiratory failure until transplantation.

Key words: End-stage lung disease, cystic fibrosis, NIV






Merit Research Journals© 2017 || Advertisement | Privacy policy.